Merck & Co. is a leading global pharmaceutical company that has made notable advancements in ESG initiatives. The company has set ambitious targets for carbon reduction, with a focus on sustainable manufacturing and a commitment to achieving net-zero emissions by 2050. Merck’s ESG rating is supported by its pioneering work in cancer treatments and other life-saving medications, as well as its focus on global health access. However, Merck has faced criticism related to the high cost of its medicines and the accessibility of its treatments in low-income countries. Its ESG score is also impacted by concerns about its pricing policies and governance practices, including transparency around drug patents. For a full overview of Merck’s ESG practices, refer to the latest Merck ESG report, which provides an honest assessment of the company's progress and challenges.